Published by Coherent Market Insights
Posted on September 27, 2021
4 min readLast updated: February 2, 2026
The VTE market is expanding due to rising prevalence and new treatments. Key regions include North America and Europe, with major players like Pfizer and Bayer.
“The Venous Thromboembolism (VTE) Market 2021 – 2027 report covers the important factors driving the growth of the market, untapped opportunities for manufacturers, trends and developments shaping the dynamics of the market and other insights across various key segments.”
Click Here To Get Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/188
Venous thromboembolism (VTE) is the formation of blood clots in the bloodstream. Two main types of venous thromboembolism are pulmonary embolism and deep vein thrombosis. The formation of blood clots in a deep vein is called deep vein thrombosis, while the deep vein thrombosis formed breaks the clot and travels to the lungs, known as pulmonary embolism. Pulmonary embolism occurs in almost one-third of patients suffering from deep vein thrombosis. VTE can occur at any age, however, it is common in adults aged 60 and above. Moreover, people whose blood is thicker than normal, older, overweight, or suffer from some other diseases such as cancer or autoimmune disorders are at a higher risk of VTE.
VTE affects both men and women equally. Around 60% of VTE cases occur during or after hospitalization. VTE is the third most common cardiovascular disease after coronary artery disease and stroke, and the leading cause of death and disability worldwide. It requires immediate medical treatment that primarily focuses on breaking or preventing the formation of blood clots. Treatment includes blood-thinning agents such as thrombolytic therapy, mechanical devices, and anticoagulants. Increasing prevalence of venous thromboembolism worldwide is expected to drive the venous thromboembolism market growth. According to the International Society on Thrombosis and Hemostasis, Inc., around 10 million cases of VTE occur annually.
Moreover, increasing research and development activities and increasing product approvals from regulatory bodies, such as the Food and Drugs Administration (FDA), are expected to propel the growth of the venous thromboembolism market. For instance, in 2019, Pfizer, received FDA approval for FRAGMIN, for the treatment of VTE in pediatric patients, aged 1 month and above. Moreover, Bayer and JNJ announced new results from the phase III study in children with VTE. However, rising consumer interest towards drug-based VTE treatment is expected to hamper the market growth.
In terms of geography, the venous thromboembolism market is divided into six regions, such as North America, Europe, Asia Pacific, South America, Middle East, and Africa. According to the International Society on Thrombosis and Hemostasis, Inc., every year, around 100,000 to 300,000 VTE-related deaths occur in the U.S. However, the number is much higher in Europe, with around 544,000 deaths every year. This preventable health condition is usually overlooked as a major public health problem leading to deaths. Increasing demand for cost-effective treatment and the well-established healthcare infrastructure in North America and the Asia Pacific is also expected to foster the venous thromboembolism market growth.
Top Key Players Include In Venous Thromboembolism (VTE) Market: Pfizer Inc., Boehringer Ingelheim GmbH, Sanofi S.A., Abbott Laboratories, Dupont Pharm Co, Bristol-Myers Squibb Company, Merck & Co. Inc., Bayer AG, Upsher-Smith Laboratories, Inc., and 3M Health Care.
The Venous Thromboembolism (VTE) Market is displayed in 13 Chapters:
Chapter 1: Market Overview, Drivers, Restraints and Opportunities
Chapter 2: Market Competition by Manufacturers
Chapter 3: Production by Regions
Chapter 4: Consumption by Regions
Chapter 5: Production, By Types, Revenue and Market share by Types
Chapter 6: Consumption, By Applications, Market share (%) and Growth Rate by Applications
Chapter 7: Complete profiling and analysis of Manufacturers
Chapter 8: Manufacturing cost analysis, Raw materials analysis, Region-wise manufacturing expenses
Chapter 9: Industrial Chain, Sourcing Strategy and Downstream Buyers
Chapter 10: Marketing Strategy Analysis, Distributors/Traders
Chapter 11: Market Effect Factors Analysis
Chapter 12: Market Forecast
Chapter 13: Venous Thromboembolism (VTE) Research Findings and Conclusion, Appendix, methodology and data source
Get This premium report with Instant US$ 2000 discount @ https://www.coherentmarketinsights.com/promo/buynow/188
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com
Visit Our Blog For More Such Reports: https://www.coherentmarketinsights.com/blog
The post Venous Thromboembolism (VTE) Market Technology Advancement and Growth 2021 to 2027 appeared first on Gatorledger.
The article discusses the growth and technological advancements in the Venous Thromboembolism market from 2021 to 2027.
Key drivers include increasing prevalence of VTE, R&D activities, and FDA approvals for new treatments.
North America, Europe, and Asia Pacific are significant regions for VTE market growth.
Explore more articles in the Research Reports category
